1. Luo, J.Q., L.Y. Wang, F.Z. He, N.L. Sun and G.F. Tang et al., 2013. Effect of NR3C2 genetic polymorphisms on the blood pressure response to enalapril treatment. Pharmacogenomics,. .
   Direct Link  |  
2. Li, X., F.M. Lian, D. Guo, L. Fan and J. Tang et al., 2013. The rs1142345 in TPMT affects the therapeutic effect of traditional hypoglycemic herbs in prediabetes. Evid Based Complement Altern. Med., Vol. 2013. 10.1155/2013/327629.
   CrossRef  |  
3. Li, H., W. Zhang and H. Zhou, 2013. Electrochemical biosensor based on base stacking-dependent DNA hybridization assay for protein detection. Anal. Biochem., 10.1016/j.ab.2013.12.019.
   CrossRef  |  
4. He, F.Z., H.L. McLeod and W. Zhang, 2013. Current pharmacogenomic studies on hERG potassium channels. Trends Mol. Med., 19: 227-238.
   CrossRef  |  
5. He, F., J. Luo, Z. Luo, L. Fan and Y. He et al., 2013. The KCNH2 genetic polymorphism (1956, C>T) is a novel biomarker that is associated with CCB and α,β-ADR blocker response in EH patients in China. PLoS One, Vol. 8. 10.1371/journal.pone.0061317.
   CrossRef  |  
6. Chen, Y., W. Zhang, W.H. Huang, Z.R. Tan, Y.C. Wang, X. Huang and H.H. Zhou, 2013. Effect of a single-dose rifampin on the pharmacokinetics of pitavastatin in healthy volunteers. Eur. J. Clin. Pharmacol., 69: 1933-1938.
   CrossRef  |  
7. Chen, W.Q., Y. Shu, Q. Li, L.Y. Xu and W.R. Mary et al., 2013. Polymorphism of ORM1 is associated with the pharmacokinetics of telmisartan. PLoS One, Vol. 8. 10.1371/journal.pone.0070341.
   CrossRef  |  
8. Zhang, W., T.Y.K. Chan, L. Fan, Y. Guo and H.H. Zhou, 2012. Translating pharmacogenomics into personalized medicine and drug development. Pers. Med., 9: 93-97.
   CrossRef  |  
9. Zhang, W., M.W. Roederer, W.Q. Chen, L. Fan and H.H. Zhou, 2012. Pharmacogenetics of drugs withdrawn from the market. Pharmacogenomics, 13: 223-231.
   CrossRef  |  
10. Wu, L.X., C.X. Guo, W.Q. Chen, G. Wang and L. Fan et al., 2012. Inhibition of the organic anion-transporting polypeptide 1B1 by quercetin: An in vitro and in vivo assessment. Br. J. Clin. Pharmacol., 73: 750-757.
    CrossRef  |  
11. Wu, L.X., C.X. Guo, Q. Qu, J. Yu and W.Q. Chen et al., 2012. Effects of natural products on the function of human organic anion transporting polypeptide 1B1. Xenobiotica, 42: 339-348.
    CrossRef  |  
12. Qin, W.J., W. Zhang, Z.Q. Liu, X.P. Chen and Z.R. Tan et al., 2012. Rapid clinical induction of bupropion hydroxylation by metamizole in healthy Chinese men. Br. J. Clin. Pharmacol., 74: 999-1004.
    CrossRef  |  
13. Guo, C.X., Q. Pei, J.Y. Yin, X.D. Peng and B.T. Zhou et al., 2012. Effects of Ginkgo biloba extracts on pharmacokinetics and efficacy of atorvastatin based on plasma indices. Xenobiotica, 42: 784-790.
    CrossRef  |  
14. Cao, S., G. Zhou, D.S.O. Yang, H. Wu and K. Xiao et al., 2012. Pharmacokinetic interactions between ilaprazole and clarithromycin following ilaprazole, clarithromycin and amoxicillin triple therapy. Acta Pharmacol. Sin., 33: 1095-1100.
    CrossRef  |  Direct Link  |  
15. Roederer, M.W., F. Sanchez-Giron, K. Kalideen, W. Kudzi, H.L. McLeod and W. Zhang, 2011. Pharmacogenetics and rational drug use around the world. Pharmacogenomics, 12: 897-905.
    CrossRef  |  Direct Link  |  
16. Fan, L., G. Zhou, D. Gou, Y.L. Liu and W.Q. Chen et al., 2011. The pregnane X receptor agonist St John's wort has no effects on the pharmacokinetics and pharmacodynamics of repaglinide. Clin. Pharmacolkinet, 50: 605-611.
    CrossRef  |  
17. Zhou, G., S. Shi, W. Zhang, Z. Tan and Y. Chen et al., 2010. Identification of ilaprazole metabolites in human urine by HPLC-ESI-MS/MS and HPLC-NMR experiments. Biomed. Chromatogr., 24: 1130-1135.
    CrossRef  |  
18. He, Y.J., W. Zhang, Y. Chen, D. Guo and J.H. Tu et al., 2009. Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin. Chim. Acta, 405: 49-52.
    CrossRef  |  
19. Zhang, W., S. Deng, X.P. Chen, G. Zhou and H.T. Xie et al., 2008. Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: A randomized, single-blind, placebo-controlled, crossover study. Clin. Ther., 30: 1283-1289.
    Direct Link  |  
20. Li, Y., W. Zhang, D. Guo, G. Zhou, H. Zhou and Z. Xiao, 2008. Pharmacokinetics of the new proton pump inhibitor ilaprazole in Chinese healthy subjects in relation to CYP3A5 and CYP2C19 genotypes. Clin. Chim. Acta, 391: 60-67.
    CrossRef  |  
21. He, Y.J., W. Zhang, J.H. Tu, J. Kirchheiner and Y. Chen et al., 2008. HNF1a inhibitor ursodeoxycholic acid (UDCA) influences pharmacokinetics of the OATP1B1 substrate rosuvastatin and bilirubin. Drug Metab. Dispos., 36: 1453-1456.
22. Chen, B.L., W. Zhang, Q. Li, Y.L. Li and Y.J. He et al., 2008. Inhibition of ADP-induced platelet aggregation by clopidogrel is related to CYP2C19 genetic polymorphisms. Clin. Exp. Pharmacol. Physiol., 35: 904-908.
    CrossRef  |  
23. Zhang, W., Y.J. He, G. Zhou, L. Fan and Q. Li et al., 2007. OATP1B1 polymorphism is a major determinant of serum bilirubin level but not associated with rifampicin-mediated bilirubin elevation. Clin. Exp. Pharmacol. Physiol., 34: 1240-1244.
    CrossRef  |  
24. Fan, L., W. Zhang, D. Gou, Z.R. Tan and P. Xu et al., 2007. The effect of herbal medicine baicalin on pharmacokinetics of rosuvastatin, substrate of organic anion-transporting polypeptide 1B1. Clin. Pharmacol. Ther., 28: 1685-1692.
25. Zhang, W., Y.J. He, C.T. Han, Z.Q. Liu and Q. Li et al., 2006. Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide. Br. J. Clin. Pharmacol., 62: 567-572.
    Direct Link  |  
26. Zhang, W., B.N. Yu, Y.J. He, L. Fan and Q. Li et al., 2006. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin. Chim. Acta, 373: 99-103.
    CrossRef  |  
27. Zhang, W., B.L. Chen, V. Ozdemir, Y.J. He and G. Zhou et al., 2006. SLCO1B1 521T→C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients. Br. J. Clin. Pharmacol., 64: 346-352.
    CrossRef  |  
28. Liu, Y.L., W. Zhang, Z.R. Tan, D.S. Ouyang and C.H. Luo et al., 2006. Metabolisms of lornoxicam and its major metabolite 5'-hydroxy lornoxicam related to CYP2C9 Genotype in healthy subjects. Clin. Chim. Acta, 364: 287-291.